Chemomab Therapeutics (CMMB) sets 1-for-4 reverse ADS split effective Aug 26

Rhea-AI Filing Summary

Chemomab Therapeutics Ltd. is changing the ratio of its American Depositary Shares (ADSs) to ordinary shares. Each ADS, which currently represents twenty ordinary shares, will represent eighty ordinary shares after the change, effectively a one-for-four reverse ADS split for ADS holders. The ratio change will take effect on August 26, 2025.

The Company’s ADSs will continue to trade on the Nasdaq Capital Market under the ticker CMMB, with a new CUSIP number of 16385C203. The Bank of New York Mellon, as depositary bank, will exchange every four existing ADSs for one new ADS on the effective date. No new ADSs will be issued in connection with this adjustment, and any fractional ADS positions will be aggregated, sold by the depositary, and the net cash proceeds distributed to affected ADS holders.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number 001-38807

CHEMOMAB THERAPEUTICS LTD.
(Translation of registrant’s name into English)

6 Habarzel Street, Building C, 10th Floor, Tel-Aviv, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

EXPLANATORY NOTE

Chemomab Therapeutics Ltd. (the “Company”) is announcing that it will effect a ratio adjustment of its American Depositary Shares (ADSs) to ordinary shares, no par value (“ordinary shares”), such that the current ratio of one (1) ADS representing twenty (20) ordinary shares will change to a new ratio of one (1) ADS representing eighty (80) ordinary shares (the “Ratio Change”), which Ratio Change will take effect on August 26, 2025. This ratio adjustment will essentially serve as a one-for-four reverse ADS split for ADS holders, requiring no action on their part.

The Company will continue to be traded on the Nasdaq Capital Market under the ticker “CMMB”, with an updated CUSIP Number of 16385C203. The Bank of New York Mellon, serving as the depositary bank for the Company’s ADS program, will arrange for the exchange of every four existing ADSs held for one new ADS on the effective date. There will be no issuance of new ADSs in connection with the adjustment. Any fractional shares resulting from the adjustment will be aggregated and the depositary bank will attempt to sell them and distribute the net proceeds to the respective ADS holders.

This Report on Form 6-K is hereby incorporated by reference into Company’s Registration Statements on Form F-3 (File No. 333-275002 and No. 333-281750) and Form S-8 (File No. 333-259489 and No. 333-266868).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CHEMOMAB THERAPEUTICS LTD.
Date: August 22, 2025	By:	/s/ Sigal Fattal
		Sigal Fattal
		Chief Financial Officer

FAQ

What ADS ratio change did Chemomab Therapeutics (CMMB) announce?

Chemomab Therapeutics announced a ratio adjustment of its American Depositary Shares so that each ADS, which currently represents 20 ordinary shares, will represent 80 ordinary shares. This functions as a one-for-four reverse ADS split for ADS holders.

When will Chemomab Therapeutics’ new ADS-to-share ratio take effect?

The ADS ratio change, in which one ADS will represent 80 ordinary shares, will take effect on August 26, 2025.

Will Chemomab Therapeutics (CMMB) remain listed on Nasdaq after the ADS ratio change?

Yes. Chemomab Therapeutics’ ADSs will continue to trade on the Nasdaq Capital Market under the ticker CMMB, and will have an updated CUSIP number of 16385C203.

Do Chemomab ADS holders need to take any action for the reverse ADS split?

The Company states that the ratio adjustment will essentially serve as a one-for-four reverse ADS split for ADS holders, requiring no action on their part. The Bank of New York Mellon, as depositary, will arrange the exchange.

How will Chemomab handle fractional ADS positions from the ratio change?

Any fractional ADSs resulting from the adjustment will be aggregated by the depositary bank, which will attempt to sell them and distribute the net cash proceeds to the respective ADS holders.

Is Chemomab issuing new ADSs as part of this ADS ratio adjustment?

No. The Company states that there will be no issuance of new ADSs in connection with the ADS ratio adjustment.

How is this 6-K related to Chemomab’s existing registration statements?

The report is incorporated by reference into Chemomab’s Form F-3 registration statements (File Nos. 333-275002 and 333-281750) and Form S-8 registration statements (File Nos. 333-259489 and 333-266868).